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Plasmacytoid dendritic cells (pDCs) are a specific subset of naturally occurring dendritic
cells, that secrete large amounts of Type I interferon and play an important role in the
immune response against viral infection. Several studies have highlighted that they are
also effective antigen presenting cells, making them an interesting target for immunother-
apy against cancer. However, the modes of action of pDCs are not restricted to antigen
presentation and IFN secretion alone. In this review we will highlight a selection of cell
surface proteins expressed by human pDCs that may facilitate communication with other
immune cells, and we will discuss the implications of these molecules for pDC-driven
immune responses.
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INTRODUCTION
Within the heterogeneous dendritic cell (DC) family, two main
subsets of naturally occurring blood DCs can be discriminated
based on their phenotype and functional characteristics: myeloid
DCs (mDCs) and plasmacytoid dendritic cells (pDCs). The mDC
subset can be further divided in CD1c+ and CD141+, which show
a high level of similarity in protein expression yet have also specific
functions in the initiation of adaptive immune responses. CD1c+
mDCs have been shown to readily stimulate naïve CD4+ T cells
and to secrete high amounts of IL-12 in response to toll-like recep-
tor (TLR) ligation, whereas CD141+ DCs do not secrete much
IL-12 but are well equipped to take up dead and necrotic cells
for subsequent cross presentation of derived antigens to CD8+
T cells (1–4). In contrast to mDCs, pDCs have a very different
protein expression profile reflecting their important and unique
function in the secretion of IFN-α and anti-viral immune response
(1, 2, 5). We and others have however recently demonstrated that
like mDCs, pDCs are also very well capable of presenting both
soluble and particulate exogenous antigens on both major histo-
compatibility complex (MHC) class I and II (6). In recent years,
numerous studies have been performed to characterize the expres-
sion of pathogen recognition receptors (PRRs), TLRs, Fc receptors,
C-type lectin (CTL) receptors, and other surface receptors on these
cells (7–13). Furthermore, these studies have emphasized both
similarities and differences between DC subtypes in their cytokine
release profiles, and their ability to acquire, process, and present
antigens (5, 14–17). These characteristics of the different DC sub-
types have recently been reviewed extensively elsewhere (2, 4, 6,
18). Here, we will focus our attention specifically on pDCs, their
role in immunity and, more specifically, their (potential) direct
interactions with cells of the innate and adaptive immune system
via cell surface molecules. Before going into detail about these cell
surface receptors and how they mediate intercellular communica-
tion, we will first give a brief summary on general pDC function
and localization to provide a context in which these intercellular
communications take place. Although studies on murine pDCs are
numerous, and commonalities between human and murine pDCs
certainly exist, major differences between pDC of both species have
also been reported. Therefore, in order to prevent confusion we
limited ourselves to human pDCs unless explicit stated otherwise.
pDC FUNCTION
A perturbation of the homeostatic condition that sets off the
immune system can trigger either an immunogenic (immunos-
timulatory) or a tolerogenic (immunosuppressive) response,
depending on the local circumstances and type of disease.
By default, immature pDCs are tolerogenic, whereas activated
(mature) pDCs can have both immunogenic and tolerogenic
capacities depending on the local environment in which they
are activated (19–21). pDCs are characterized as Lin− MHC-
II+ CD123 (IL3R)+ CD4+ CD303(BDCA-2)+ CD304(BDCA4;
Neuropilin-1)+ and are mostly known for their ability to quickly
produce large amounts of the Type I interferons (IFNs), IFN-α, and
IFN-β, following viral infection, implicating pDCs as an impor-
tant contributor during the early phase of anti-viral response
(2, 22, 23).
The most important documented enveloped viruses known
to stimulate Type I IFN release by pDCs are human immun-
odeficiency virus type 1 (HIV-1), herpes simplex virus (HSV),
and influenza virus (24–27). Furthermore, parasites and bacteria
containing DNA with unmethylated CpG sequences can trigger
pDC activation (28–31). In addition to the anti-viral capacity,
www.frontiersin.org November 2013 | Volume 4 | Article 372 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mathan et al. Direct pDC – immune cell interactions
Type I IFN release by pDCs has also been reported to be impor-
tant for pDC survival, (m)DC-mediated CD4+ and CD8+ T cell
responses, mDC differentiation, cross presentation, upregulation
of co-stimulatory MHC molecules and activation of natural killer
(NK), and B cells (32–34).
Because of their expression of the endosomal TLRs TLR7 and 9,
pDCs, in contrast to other (immune) cells, do not need to become
infected to respond to viruses or intracellular bacteria (35, 36).
TLR7 recognizes guanosine or uridine-rich, single-stranded RNA
from viruses or synthetic products like guanosine analogs such
as R848. TLR9 senses single stranded DNA containing unmethy-
lated CpG motifs, which are usually found in bacterial and viral
genomes, and additionally senses for synthetic oligonucleotides,
such as CpG-ODN (37, 38). pDCs show differential responses
based on the type of virus/bacteria that is recognized, which has
been suggested to be attributed to a different site of TLR activation
within the endosomal system (39). For example, depending on the
subtype of CpG recognized (CpG-A, CpG-B, CpG-C) the outcome
of the response can be different. While CpG-A, that triggers TLR9
in early endosomes, induces IFN-α release, CpG-B, signaling from
late endosomes, leads to tumor necrosis factor α (TNF-α) and
IL-6 production by pDCs (40). In addition, the interplay of the
various PRRs tailors the pDC response to a specific pathogenic
threat. In addition to TLRs, pDCs express several CLRs, including
BDCA-2, DEC-205, dectin-1 and DCIR, and Fc receptor CD32,
but they lack for instance DC-SIGN (22, 41–45). Although the full
repertoire of receptors is still under investigation, most of these
receptors drive antigen uptake, and in concert with TLR7 and 9,
coordinate pDC-mediated immune responses.
pDC LOCALIZATION
Immature pDCs circulate in the blood but have been equipped
with migratory capacities as they are found within lymph nodes
(LNs), tumors, and near sites of viral/bacterial infection (46,
47). At all these sites pDCs are able to promote inflammatory
responses by attracting other immune cells through chemokine
release, and the subsequent modulation of these cells via cytokines
or direct cell–cell interactions (48–51). However, in contrast to
human myeloid mDCs or murine pDCs studies, reports addressing
which inflammatory chemokines and adhesion receptors specif-
ically drive migration of human pDCs are scarce (52). Human
pDCs express chemotactic receptors C-C chemokine receptor
type 7 (CCR7), chemokine (C-X-C motif) receptor 3 (CXCR3),
CXCR4, and ChemR23 (CMKLR1) that likely mediate migration
of pDCs into lymphoid organs and/or into inflamed tissue (48,
52–55). However, due to conflicting reports the role of classi-
cal lymphoid tissue CCR7− Chemokine (C-C motif) ligand 21
(CCL21)/CCL19 pathways in resting human pDCs, is not conclu-
sive yet (53, 56). Several studies show a high expression of CCR7 on
“resting” blood DCs while others have reported a very low or a lack
of expression on resting pDCs (53, 57–60). Similar to mDCs and
murine pDCs, human pDCs upregulate expression of CCR7 upon
TLR stimulation and migrate toward CCL21 molecules, suggesting
an important role of CCR7 at least for the migration of mature
pDCs to the LN (55). Furthermore IL-3 produced by T cells in
the LN or by activated endothelial cells can lead to the upregula-
tion of chemokine receptor 6 (CCR6) and CCR10 that may drive
migration of activated IFN producing pDCs to inflamed skin or
mucosa (61).
In contrast to mDCs, which migrate from peripheral tissue to
secondary lymphoid organs via afferent lymphatic vessels, pDCs
have been described to migrate to the LN mostly directly from the
blood via high endothelial venules (HEVs) (62, 63). Since pDCs
first need to engage and traverse the endothelial cells lining of
the blood vessels, endothelial cells likely represent the first cellular
contact pDCs will engage in after leaving the blood stream. pDC
would require a similar migration capacity to enter into inflamed
or tumor tissue, which also requires interaction with endothelial
cells and extravasation. Next, within the LN, or at the site of infec-
tious or cancerous lesions, pDCs may encounter various immune
cells. In the LN, pDC have been found in close contact with T
lymphocytes, Invariant Natural Killer T (iNKT) cells, B lympho-
cytes, and NK cells (21, 24, 42, 64–66). At sites of infection pDCs
might activate or get activated by mDCs and NK cells, whereas
within the tumor microenvironment pDCs are known to interact
predominantly with tumor cells and regulatory T (Treg) cells (67,
68). Below we have summarized the evidence reported thus far
for each of these (potential) interactions, and the circumstances
under which they occur (Figure 1).
ENDOTHELIAL CELLS
Depending on their location (peripheral tissue or LN) and acti-
vation state, endothelial cells have been shown to express distinct
cell surface molecules and to secrete a variety of chemokines and
cytokines that may aid leukocyte transmigration and regulate the
activation state of the migrating cells (69). Endothelial cells thus
not only facilitate pDC transmigration into the site of infection,
the tumor lesion, or the LN but may also have the potency to
influence pDCs mediated immune responses trough pro- or anti-
inflammatory cytokines as well as growth factors (69). Indeed,
endothelial cells also produce IL-3 and VEGF that bind and trig-
ger pDC marker proteins CD123 and BDCA4 respectively, and
likely will promote pDC survival and migration after crossing
the endothelial barrier. Documentation however of the crosstalk
between human pDCs and endothelia is scarce and limited to a
few recent studies that we will discuss. Intriguingly, and in con-
trast to murine pDCs, both resting and matured human pDCs
(stimulated by influenza virus) uniquely express the receptor for
chemerin, ChemR23 (48). Chemerin is present on the surface of
endothelial cells in the lumen of HEVs as well as in blood vessels of
inflamed tissue. The interaction between endothelial cell-bound
chemerin and pDC ChemR23 seems to play a crucial role in the
migration of pDC from the blood both into LNs and into inflamed
tissue (Figure 2) (48, 70, 71). Like pDCs, T cells also migrate from
the blood to the LN via HEVs and thus pDCs may exploit a similar
set of molecules as used by T cells. Indeed, pDCs express adhesion
molecules CD31, CD43, CD44, CD47, CD62L, CD99, and CD162
(SELPLG, CLA) that may play an important role in the tethering
and rolling of pDCs on endothelial cells, but for most of these mol-
ecules, functional data for a role on human pDCs is lacking (54, 72,
73). The Lymphocyte function-associated antigen 1 (LFA-1) and
very late antigen 1 (VLA-1) (CD49a/CD29) molecules might play
an important role in subsequent firm adhesion and transmigration
of pDCs (72). Although the expression of all these molecules was
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FIGURE 1 | Plasmacytoid dendritic cell have the capacity to interact with
various immune cells through an array of surface molecules. The
expressed surface molecules of each cell type are divided into confirmed and
potential interactions. The “confirmed” molecules have been reported to have
a functional effect. Molecules listed in the “potential” column are molecules
that have been found on human pDC but without functional data reported in
literature. Molecules playing a potential role in humans, but already confirmed
with functional studies in mouse are depicted in red.
FIGURE 2 | Ligand/receptor paring of a pDC with an endothelial cell and the maturation state/activation stimuli associated with ligand or receptor
expression on the pDC surface.
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initially only detected by microarray, with the exception of CD44,
most were confirmed by flow cytometry (74). Furthermore, flow
cytometry demonstrated that expression of both CD62L (moder-
ately) and CD99 was downregulated upon exposure to IL-3 and
HSV, indicating that activated pDCs may take different migra-
tory routes compared to their immature counterparts (74). While
immature pDCs express CD62L and use HEVs to migrate into the
LN, downregulation of CD62L on mature pDCs suggests that these
cells enter LN without passing HEV, but rather through the lym-
phatic vessels. Furthermore, another study identified a cleavage of
CD62L after entering the HEV suggesting this molecule may have
become obsolete for pDCs following this pathway (75). In skin, in
contrast, after transversing the vessel wall expression of CD62L on
pDC remains high, indicating that in this case it may still have a
function at a later stage (54).
In summary, although there is evidence for Intercellular Adhe-
sion Molecule 1 (ICAM-1)/LFA, CD31/CD38, and CD34/CD62L
interaction between pDCs and endothelial cells, until now, only
the chemerin/ChemR23 interaction has been conclusively demon-
strated to play a role during the migration process. The migratory
function of the other adhesion molecules reportedly expressed by
human pDC are currently only hypothetical and based on knowl-
edge from other leukocytes or murine cells. Furthermore also the
role of endothelia in the regulation of the pDC activation state
awaits further study.
T CELLS
During infection, immature DCs located in the inflamed tissue get
activated through pathogenic interaction and pro-inflammatory
cytokines. Mature (activated) DCs subsequently translocate to the
LN and induce naïve T cells to differentiate into effector T cells.
Based on the repertoire of danger signals, effector T cells will
have different characteristics and will evoke a different immune
response. pDCs have an important role in coordinating such an
immune response, since the molecules involved in the interaction
between DCs and T cells determine T cell polarization (Th1, Th2,
Th17). Numerous studies have established that pDCs are bona
fide antigen presenting cells (APCs), capable of presenting exoge-
nous antigens on both MHC class I and II molecules and thus
can trigger both CD4+ T helper (Th) cells and CD8+ cytotoxic
T cells (5, 26, 76–78). The nuances of pDCs antigen process-
ing and presentation have recently been reviewed by Guery and
Hugues (42) and Nierkens et al. (79). Here, we focus our atten-
tion on how pDC cell surface receptors may skew T cell function
(Figure 3). Freshly isolated (immature) pDCs are known to induce
CD4+ T cell anergy presumably because they lack co-stimulatory
molecules; conversely, activated pDC clearly induce a broad spec-
trum of T cell differentiation, for example, Th1, Th2, Th17, and
Treg, based on the cytokines secreted and cell surface proteins
expressed (21, 80–84). Like mDCs, activated pDC express high
levels of MHC molecules and the co-stimulatory molecules CD80
(B7-1), CD86 (B7-2), and CD83 to present antigens and fully
license and activate T cells (5,6). Several studies have demonstrated
that (virally) matured pDCs, through the release of cytokines,
mostly induce a Th1 phenotype (IFN-γ/Il-12 in response to CpG,
virus) but Th2 (IL-4) and Th17 (IL-17) skewing has also been
reported when pDC are activated with IL-3 or CD40 and TLR7
ligands, respectively (82, 85–87). Furthermore IL-21 (produced
in the LN) was shown to trigger the release of Granzyme B by
TLR-activated pDCs thereby dampening CD4+ T cell prolifer-
ation (88). Together these studies show how pDCs may regulate
immune responses. Apart from cytokines released by pDCs, several
pDC surface receptors may directly affect T cell skewing and func-
tion, including the inducible T-cell co-stimulator ligand (ICOSL).
pDCs express ICOSLG when activated by CpG-(A, B, and C) IL-
3/CD40L or virus (Flu/HSV) (83). ICOSLG is the ligand for the
FIGURE 3 | Ligand/receptor paring of a pDC with aT cell and the maturation state/activation stimuli associated with ligand or receptor expression on
the pDC surface.
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T-cell-specific cell surface receptor inducible costimulator (ICOS)
and has been shown to trigger naive CD4+ T cells to produce IL-10
during both pDC Th1 or Th2 skewing in response to CpG/virally
or IL-3/CD40L-matured pDCs, respectively (83, 84). It has been
suggested that ICOSL-activated pDCs generate IL-10 producing
Tregs to dampen immune responses, preventing excessive inflam-
mation (83). Furthermore TLR activated, but not resting pDCs
and mDCs, express programed death receptor-ligand 1 (PD-L1),
which may induce T cells anergy/suppresses T cell activation by
binding to its receptor, program death ligand 1 (PD1), which
is expressed by T cells (89, 90). The immunosuppressive effect
of PD-L1 has been confirmed by using blocking antibodies on
DCs, and additionally in follow-up studies where blocking the
PD-L1/PD1 interaction lead to “enhanced tumor-specific T cell
expansion and activation” (6, 91, 92). The surface receptor OX40,
which is expressed on IL-3 activated pDCs, can induce a Th2 T cell
response resulting in IL-4, IL-5, and IL-13 release by CD4+ T cells
(93, 94).
Furthermore, after stimulation either with synthetic TLR7 and
9 agonists or with the natural TLR7 agonists, like influenza virus or
UV-inactivated HSV type 1(HSVUV) pDCs can induce programed
cell death/apoptosis, by expressing tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) (74, 95, 96). TRAIL expression
on pDCs uniquely correlates with viral load, and the capacity to
kill HIV-infected CD4+ T cells by binding to the TRAIL receptor,
a process described as “TRAIL-dependent pDC-mediated killing”
(97). However, given the very limited cell numbers, it remains to be
seen how important TRAIL+ pDCs are in clearing a viral infection
via the direct killing of infected cells (97, 98).
Another surface molecule expressed on TLR-activated pDCs
that may affect T cell function is the lectin-like transcript 1 (LLT1),
which in addition to activated pDCs, is expressed by most acti-
vated lymphocytes (including B cells, T cells, and NK cells) and
mature monocyte-derived DCs (99). LLT1 is a ligand of CD161
(NKR-P1A), which is expressed by subsets of T cells (e.g., Th1,
Th17, and a subpopulation of CD8+ T cells) and NK cells. When
ligated LLT1 triggers T cell proliferation and IFN-γ secretion as
well as inhibition of NK cell cytotoxicity (99–102). Thus, LLT1 on
pDCs may serve as a co-stimulatory molecule, and after binding
to CD161 expressing T cells, could drive proliferation and IFN-γ
secretion (51).
So far, we discussed how pDC receptors may affect T cell func-
tion but of course, conversely, T cells may also influence pDC
function. In a multicellular immune cell signaling cascade the pre-
sentation of viral antigens by pDCs brings about IL-2 release by
T cells as well as CD40L expression. T cell CD40L upon binding
to CD40 on pDCs, triggers IL-6 release by pDC, which in turn
enables B cell plasma blasts to become antibody-secreting plasma
cells (Figure 8) (21, 64).
In summary, while immature pDCs predominantly induce T
cell anergy, their activated counterparts may have either inhibitory
or activating effects on T cells. Which of the latter in the case
depends on stimuli that trigger pDC maturation and which
cytokines and surface molecules are expressed as a result. Thus
pDCs play pivotal role in T cell activation and fine tuning of the
adaptive immune response.
iNKT CELLS
Natural Killer T (NKT) cells form a specialized T cell subset
expressing a semi-invariant T cell receptor (TCR-αβ) and surface
antigens traditionally associated with NK cells. The unique TCR
on their cell surface enables NKT cells to recognize glycolipid anti-
gens rather than peptides, presented in the context of the MHC
class I-like molecule, CD1d (103). The most well characterized
subset of NKT cells are called iNKT cells, since they express an
invariant TCR-α chain, and are reactive to the potent NKT cell
agonists α-galactosylceramide (α-GalCer) (103).
Studies have shown that pDCs interact with iNKT cells directly,
both via cell–cell interactions and by cytokine release (104). In con-
trast to the mDCs, pDCs lack the expression of CD1d, which is an
important molecule for crosstalk with iNKT cells (105). Nonethe-
less, over the past few years the ability of iNKT cell to“sense”subtle
changes within their microenvironment in a CD1d-independent
mechanism, uncovered that cytokines released by pDCs are essen-
tial (106, 107). Indeed, CpG activated pDCs upregulate activation
markers on iNKT cells via TNF-α and IFN-α release, and selec-
tively enhance double-negative iNKT cell survival but not that
of other NKT cell populations (104). However, the interplay of
iNKT cells with pDCs alone is not sufficient for iNKT expansion
and does not lead to a cytokine release by iNKT cells. Rather,
the CpG activated pDCs enables the iNKT cells to productively
interact with CD1d expressing mDCs, thus initiating an immune
response (61). Both iNKT cells and mDCs lack expression of TLR9
and are therefore unresponsive to CpG; hence, cytokines released
upon ligation of TLR9 on pDCs modulate the tissue microenvi-
ronment. Not only cytokines, but also a direct interaction between
pDCs and iNKT cells may be of importance; CpG-stimulated
pDCs express the ligand CD252 (OX40L), which binds CD134
(OX40) present on the surface of iNKT cells, and augments IFN-γ
release by iNKT cells in response to lipid antigen presentation by
mDCs (Figure 4) (66). Further support for such a direct interac-
tion between pDCs and iNKT cells via OX40L/OX40 comes from
murine studies (108–110).
In summary, the interaction between iNKT cells and pDCs can
be both via cytokines and via direct cell interaction. The role so
far seems to facilitate the activation of iNKT by CD1d expressing
mDCs. This may become important particularly in situation when
TLR9 ligands are available. So far, only OX40L/OX40 are known
to play a role in the direct pDC/iNKT cell cross talk.
B CELLS
B cells are the only cells that produce antibodies, and therefore,
have a critical role in the humoral immune response. Release of
Type I IFNs by pDCs leads to an increase of TLR7 and several
activation markers on B cells (111, 112). Moreover, as outlined
above, pDCs, in concert with T cells, control B cell differentiation
into plasma cells via the secretion of IFN-α and IL-6 (64). In addi-
tion, pDCs can affect B cells via direct cell–cell contact. Several
studies have shown the importance of CD40-CD40L interactions
between B cells and pDCs (Figure 5) (24, 64, 65). In addition, upon
activation with CpG, pDCs were demonstrated to interact with B
cells via CD70/CD27 molecules. This interaction results in B cell
growth, differentiation, and immunoglobulin secretion (113).
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FIGURE 4 | Ligand/receptor paring of a pDC with an iNKT cell and the maturation state/activation stimuli associated with ligand or receptor
expression on the pDC surface.
FIGURE 5 | Ligand/receptor paring of a pDC with a B cell and the maturation state/activation stimuli associated with ligand or receptor expression
on the pDC surface.
Furthermore, recent in vitro studies have shown that activated B
cells are able to stimulate matured pDC to produce IFN-α by direct
cell–cell contact (114). Blocking the surface molecules OX40L,
CD27, CD40, or CD40L with monoclonal antibodies did not
influence the effect of B cells on pDC-derived IFN-α production.
However, the IFN-α production by pDCs was significantly reduced
when blocking LFA-1 or PECAM-1 (CD31) by 50% and 80%,
respectively, indicating that these molecules are at least partially
responsible for B cell mediated pDCs activation (114).
Taken together, pDCs and B cells are able to induce recip-
rocal cytokine release and activation by both soluble mediators
and direct cell–cell interaction, and so far have been found to be
predominantly stimulatory in nature (64, 113, 114).
mDCs
Synergism of mDCs and pDCs are not restricted to the activation
of NKT cells. pDCs and mDCs have been demonstrated to be in
close contact in vivo at steady state as well as under inflammatory
conditions, and it has been suggested that they act synergistically
to induce more potent immune responses (115–117). Upon stim-
ulation both mDCs and pDCs function as APCs and follow a sim-
ilar maturation program, and express the co-stimulatory markers
CD40, CD80, CD83, and CD86 to interact with T cells (17, 118).
However, there are complementary differences especially in the
expression of PRRs (e.g., TLRs, CLRs) and thus in their response
to pathogenic triggers. Whereas mDC subtypes express TLR1, 2, 3,
4, 5, 6, 8, and 10, but no TLR7 and 9, the expression of these TLRs
on pDCs is the exactly opposite except from TLR2 and 10, which
are shared (7, 8, 35, 119–122). pDCs respond to TLR7 and 9 lig-
ands with large amounts of IFN-α and TNF-α (123). In contrast,
mDCs release very different cytokines, primarily IL-1β, IL-8, IL-
6, IL-10, IL-12p70, TNF-α to variable extents, upon triggering of
their TLRs (7, 118, 122). Upon viral infection pDCs are known to
respond quicker and with larger amounts of cytokines than mDCs
(124). Thus pDCs and mDCs have non-overlapping sensitivities
to invading pathogens, and accumulating reports suggest that
pDC and CD1c-mDC may cross-activate each other for a more
effective immune response. Crosstalk may occur in a paracrine
fashion through cytokines like Type I IFNs and TNF-α but also
via direct cell contact (118, 125). In a paracrine fashion TNF-
α expressed by pDC can cross-activate co-cultured CD1c-mDCs
(126). However, there is clear evidence to suggest that CD1c-mDCs
and pDCs in other cases require close contact for some parts of this
crosstalk, until now it is unclear what molecules are involved (118).
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Recent studies by Piccioli et al. implies that several members of
the TNF family, CD40L/CD40, OX40L, HEVML, RANKL, CD27,
CD30L, glucocorticoid-induced tumor necrosis factor receptor-
ligand (GITRL), and 4-1BB are redundant in the CD1c-mDC/pDC
cross talk (9). Experimental evidence for the absence of a role for
any of these interactions however was so far not reported but only
came from unpublished blocking experiments mentioned in these
studies, making it extremely hard to deduce whether these interac-
tions can and should be excluded completely (9, 118). Interestingly,
murine models do suggest that the TNF member CD40/CD40L
may have a crucial role in the CD1c-mDC/pDC cross talk, yet
this result needs to be recapitulated in human CD1c-mDC/pDC
assays (9).
So far only for the NOTCH receptor-ligand interaction evi-
dence is provided for a role in the communication between
pDCs and CD1c-mDCs but again experimental evidence is scant
(Figure 6) (117). With co-culture experiments they demonstrated
that LPS-activated CD1c-mDCs caused an upregulation of mat-
uration marker (CD25, CD86) on the pDC surface and increased
IL-6 and CCL19 release in the supernatant. To confirm the involve-
ment of NOTCH pathway, experiments with γ-secretase/NOTCH
inhibitor DAPT and soluble NOTCH ligands were preformed and
showed a reduced effect on Notch target genes. Activation of
the NOTCH pathway upon CD1c-mDC/pDC interaction suggests
that this intercellular contact promotes an immune stimulatory
response, however, further experiments are needed to unravel the
exact mechanism and other molecules potentially involved in this
CD1c-mDC/pDC cross talk (117).
Another possible candidate for the interaction between pDC
and CD1c-mDC is ICAM-1, expressed on both, pDCs and
mDCs, and known as an widespread adhesion molecule with
co-stimulatory activity on other immune cells (127). ICAM-1
was found to be strongly upregulated on pDC upon stimula-
tion with TLR9 ligand CpG, while its matching receptor LFA-1
(CD11a/CD18) is constitutively expressed on CD1c-mDCs (9).
Taken together, there is clear evidence that direct cellular inter-
actions are indeed important for CD1c-mDC/pDC cross talk in
humans, similar to what was observed in murine studies. However,
besides NOTCH receptor-ligand interactions, any experimental
evidence that argues in favor of or against the involvement of other
specific receptor-ligand interactions is so far lacking (9, 118).
NK CELLS
Natural killer cells belong to the innate immune system and are
able to respond rapidly to virally infected cells and to tumor for-
mation. This is due to their unique ability to recognize stressed
cells or the absence of MHC on the surface of infected or malig-
nantly transformed cells, and their subsequent ability to lyse these
cells. The bi-directional pDC-NK cell interaction is known to play
an important role in host defense, and again is mediated both
by cytokines and via direct cell contact (128, 129). Type I IFNs
secreted by pDCs have long been known to enhance the cytolytic
potential of NK cells, and NK cells co-cultured with pDCs are
more activated, and have increased cytolytic activity (49, 50, 130–
133). pDCs and NK cells have been found in close proximity in
the T cells areas of human tonsils (50). In addition, during infec-
tion or in case of a malignancy, pDCs and NK cells may migrate
simultaneously to the site of the lesion, for example during Her-
pes simplex infection (25). These reports demonstrate the ample
opportunities for these cells to engage in direct interactions, which
is further supported by the findings that, when co-cultured, pDCs
and NKs cells readily interact (134). Upon stimulation by a virus
or CpG, pDCs express GITRL that can bind GITR expressed by NK
cells (Figure 7). Via the (GITRL)-GITR interaction mature pDCs
enhance NK cell mediated killing as well as IFN-γ production.
To affect NK cells, however, pDCs expressing GITRL do require
the simultaneous presence of IFN-α (50). Furthermore, while the
upregulation of CD69 on the surface of NK cells depends on the
release of IFN-α and TNF-α by mature pDCs, upregulation of
HLA-DR on the surface of a subpopulation of NK cells depends
on direct pDC-NK cells contact (49). HLA-DR expressed on NK
cells is thought to play an important role in handling bacterial
infections such as Mycobacterium bovis (BCG) (135). Although
the interaction responsible for HLA-DR upregulation remains to
be elucidated, it is known that the maturation state of the pDC
is not important for the induction of HLA-DR expression on NK
cells, indicating the HLA-DR inducing factor is not affected by
pDC maturation (49, 130, 132, 136).
The bi-directional crosstalk between pDCs and NK cells also
affects pDC function; IL-2, immune complex or IL-12/IL18-
stimulated NK cells induce pDCs to release IFN-α which was
shown to depend largely on LFA-1-mediated interactions between
NK cells and pDCs, and to a lesser extent on NK cell secreted
FIGURE 6 | Ligand/receptor paring of a pDC with a mDC and the maturation state/activation stimuli associated with ligand or receptor expression on
the pDC surface.
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FIGURE 7 | Ligand/receptor paring of a pDC with an NK cell and the maturation state/activation stimuli associated with ligand or receptor expression
on the pDC surface.
MIP1α (132, 134). LFA-1 and FcγRIIIA on the pDC also increase
cytokine release by NK cells (137). Furthermore, IL-2 stimu-
lated NK cells induced pDCs to express the maturation marker
CD83, but not CD80 and CD86, in a contact dependent manner,
which also indicates the existence of different stimulatory path-
ways that can induce expression of different maturation markers
on pDCs (132).
Contact with NK cells potentially puts pDCs in danger of
becoming lysed. However, immature pDCs are protected from
NK cell mediated lysis, and this is at least partly due to the high
expression of HLA class I, and the absence of Nectin-2, the lig-
and for NK cell activating receptors DNAM-1 (132, 138). Culture
of pDCs with IL-3 however causes the upregulation of Nectin-
2 on pDCs, and makes them more susceptible to DNAM-1 and
NKp30-mediated killing (138). Activation of pDCs by TLR7 and 9
may help to prevent NK cells lysis as they express the LLT1 (LLT1
or CLEC2D; above), which is a ligand of NK cell surface protein
P1A (NKR-P1A; CD161). P1A is expressed by both NK and NKT
cells and when ligated inhibits NK cell cytolytic function and IFN-
γ release (51, 99, 101, 139). Taken together, pDCs in various modes
of action, seem to be differentially susceptible to NK cell-mediated
lysis through the absence of activating NK cell receptor-ligands, as
well as the regulated expression of ligands for NK cell inhibitory
receptors. Also, high MHC I expression is protective.
In summary, non-lethal pDC/NK cell interactions seem to play
an important role in enhancing the early immune response to a
viral or bacterial infection as pDCs activate the NK cell by pro-
ducing IFN-α and via GITRL. This feed-forward system likely
promotes NK cells to rapidly lyse infected cells (132). NK cell
activity in turn induces a further increase of IFN-α by pDCs
and promotes their maturation, which may in turn increase the
recruitment and survival of mDCs (Figure 8).
TUMOR CELLS
Several early studies have reported decreased numbers of pDCs
and mDCs in the blood of patients suffering from various types
of cancers (140–143). However, a recent study with melanoma
patients detected no significant difference between the levels of
immature pDCs in healthy donors and patients (144). Compared
to healthy volunteers, pDCs derived from melanoma patients did,
however, show a higher expression of CCR6, and increased ability
to migrate toward Chemokine (C-C motif) ligand 20 (CCL20),
a ligand for CCR6 (144). CCL20 is expressed by keratinocytes in
the skin and by melanoma cells, suggesting that the CCL20/CCR6
interaction is involved in the pDC migration process from the
blood to the tumor (145–147). Indeed, high pDC infiltration have
been observed in many types of cancer including melanoma, head
and neck cancer, ovarian and prostate cancer, and these infil-
trates mostly negatively correlate with patient survival. On the
other hand, an increase of pDCs in tumor-draining LN may be
beneficial [reviewed in (143, 148)]. pDCs infiltrated in tumor
microenvironment are mainly immature, and therefore seem to be
predominantly immunosuppressive/tolerogenic (148). In recent
years, evidence has accumulated that tumors may block anti-
tumor response by maintaining pDCs in an inactive/tolerogenic
state. Mechanisms responsible for keeping the pDC in this state
include the secretion of prostaglandin 2 (PGE2) and TGF-β, which,
in a synergistic manner inhibit pDC-derived IFN-α and TNF-α
production in response to TLR7 and 9 ligands, as well as inhibiting
CCR7 expression, thereby impairing the migration of pDCs to the
tumor-draining LN to prime T cells with tumor antigens (148–
150). In addition, there is evidence that PGE2-stimulated pDCs
indirectly support tumor cell proliferation, migration, and inva-
sion, as well as tumor angiogenesis, via the release of IL-6 and IL-8
(151–158). Furthermore, tumor-resident pDCs may also influence
tumor growth indirectly through the induction of Tregs. In epithe-
lial ovarian cancer the majority of Foxp3+ Treg cells accumulating
in the tumor microenvironment expressed the ICOS, and tumor
pDCs expressing the ICOSL were shown to be essential for the
expansion and suppressive function of these regulatory Foxp3+
Tregs (67, 68).
On their surface, unstimulated pDCs (uniquely with respect
to all other leukocytes) express the immunoglobulin-like tran-
script 7 (ILT7) protein, which is activated by binding to bone
marrow stromal cell antigen 2 (BST2, CD317; reviewed in (159)).
BST2 is expressed on human cancer cells, monocytes, and vas-
cular endothelium in response to IFN-α (Figure 9) (160–162).
Similar to BDCA-2, ILT7 forms a complex with FcεRIγ, which,
when ligated activates an immunoreceptor tyrosine-based acti-
vation motif (ITAM)-mediated signaling pathway that dampens
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FIGURE 8 | Direct cell interaction dependent on GITR/GITRL or CD40/CD40L binding and their effect on a certain cell type.
FIGURE 9 | Ligand/receptor paring of a pDC with a tumor cell and the maturation state/activation stimuli associated with ligand or receptor
expression on the pDC surface.
TLR-7 and 9-induced IFN-α and TNF-α production (163, 164).
ILT7 is downregulated upon stimulation of the pDCs by CpG,
HSV, or IL-3, suggesting that pDC maturation prior to entering the
tumor site may partly protect it from this suppressive mechanism
(159, 164, 165). In addition to ILT7, immature pDCs also express
the ITIM motif containing receptors ILT2 and ILT3 that bind to
MHC class I molecules, and an unknown ligand, respectively. Both
receptors are associated with immune tolerance, probably through
the suppression of T cell responses, and in agreement with this
notion, these receptors are downregulated upon pDC activation
(166–168). Whether these molecules may also have an active role
in the pDC-tumor cell interaction, or rather regulate pDC-T cell
activation, remains to be investigated. Likewise, there may be a yet
unappreciated role for pDC expression of NKp44, which has been
demonstrated to down modulate pDC IFN-α responses upon lig-
ation, and may be utilized by the tumor to dampen pDC-mediated
immune responses (169). Indeed, an inhibitory NKp44 ligand
complex containing HLA I and PCNA was recently reported to
be expressed by several tumor cells (159, 165, 170).
So far, most studies point out an immune suppressive role
for pDCs favoring tumor progression, however several other
studies demonstrate that the situation may be very different
if pDCs are properly activated. In this case pDCs may trigger
anti-tumor T cell-mediated immune responses (above) or even
actively kill tumor cells (171, 172). As previously discussed, in
relation to the T cell/pDC interaction, activated pDCs express
TRAIL, which induces an apoptotic process by binding to the
TRAIL receptors. Tumor cells are known to be sensitive to TRAIL,
and via this interaction could directly induce tumor cell apop-
tosis (171). Avoiding this apoptotic pathway by downregulation
of TRAIL has been reported for several cancers by numerous
studies (173).
Taken together, the suppressive tumor microenvironment
decreases the immune stimulatory functions of pDCs resulting
in tumor progression. Preventing these processes, while at the
same time activating pDCs, forms a promising target for anti-
tumor therapies. Moreover, in a recent clinical feasibility study
in our department, we demonstrated that the administration of
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autologous ex vivo-matured tumor antigen loaded pDCs proved
to be successful and induced objective clinical responses in several
patients (60).
LESS EXPLORED IN pDC CELLULAR INTERACTIONS: THE
SLAM FAMILY
Above we have provided an overview of the interactions pDCs
likely engage in during their lifecycle, as based on experimental
evidence and in vivo proximity. In addition we discussed the mol-
ecules likely to participate in these interactions. There is, however,
a poorly understood family of proteins which are highly expressed
pDCs, and which deserve more attention. This is the SLAM family
of receptors, for which a role in a diverse range of cellular inter-
actions is highly suspected, yet currently unexplored. Five family
members are expressed on the pDC surface (largely) indepen-
dent of its activation state: SLAMF2 (CD48; BLAST1), SLAMF5
(CD84), SLAMF3 (CD229; Ly9), SLAM7 (CD319, CRACC), and
NTBA (CD352) (74, 102). Except for SLAMF2 (below), these pro-
teins have in common that they engage mostly in homotypic
interactions; such interactions may occur between homotypic
cells, but also between different cell types, opening up the possibil-
ity that these molecules mediated direct cell interactions of pDCs
with each other, or with others cells also expressing these receptors
(174). Homotypic SLAM family interactions have the ability to
regulate cell activation and proliferation as well as cytolytic activ-
ity (174). SLAMF5 is highly expressed by many immune cells, and
has been shown to play a role in T cell-B cell adhesion, and for opti-
mal germinal center formation (175, 176). Furthermore SLAMF5
was detected on leukemic pDCs, and can work as an inhibitor
for FcεRI-mediated signaling in mast cells (177, 178). SLAMF3 is
also expressed on T cells. Here it reduces IFN-γ production and
ERK activation upon stimulation, and thus via this molecule pDCs
might trigger a similar response (175, 179). SLAM7, in contrast, is
widely expressed on activated B lymphocytes, NK cells, and CD8+
T lymphocytes (74, 180–182) and has been shown to promote B
cell proliferation, activate NK cell cytotoxicity (but not NK cell
proliferation) (180, 182, 183). Finally, NTBA in addition to pDCs,
is present on NK, T, and B cells where it may affect cytotoxicity
as well as the IFN-γ and TNF-α release (174, 184, 185). Interac-
tions between NTBA on pDCs and NK cells may therefore have
the potential to positively regulate both NK cells and pDCs.
In contrast to the other family members, SLAMF2 which is also
present on the surface of pDCs, engages in a heterotypic interac-
tion with family member 2B4 (CD244), and could thus play a role
in the interaction of pDCs with 2B4-expressing NK or T cells (74,
175, 186). SLAMF2 via 2B4 can activate NK cells (186).
Overall, although experiments are largely lacking, the pres-
ence of such a high number of SLAM family members on pDCs,
their homotypic interactions, as well as the known effects of their
triggering on other immune cells makes us speculate that pDCs
may very well exploit these receptors to communicate with other
immune cells.
CONCLUSION AND OUTLOOK
In this review we summarized the existing data which supports
the idea that during their life cycle, human pDCs interact with
numerous immune cells. Additionally, we have attempted to pro-
vide a contemporary overview of the molecules that drive these
interactions, and the consequences of their expression on pDCs. It
is clear that pDCs play a pivotal role in ensuring a rapid immune
response, especially upon viral infection, by strong IFN-α release,
but also via direct cell–cell interaction. Depending on the pDC
activation state, cytokines released by pDCs and direct pDCs sur-
face receptors may inhibit or activate other immune cells. This
large influential capacity of pDCs suggest that they are master
regulators of both innate and adaptive immune responses. Besides
secretion of the highly potent yet broadly acting IFN-α, pDCs have
a highly versatile repertoire of cell surface molecules to further
fine tune immune responses. These characteristics make them an
interesting and potential highly valuable therapeutic target to be
exploited or targeted in cancer therapy, infectious or autoimmune
disease. Importantly, controlling cytokine secretion and the sur-
face expression of specific receptors is essential to steer the immune
response into the desired direction. In cancer therapy, lifting the
suppressive actions of tumor-resident pDCs may greatly enhance
existing/endogenous anti-tumor immune response (187). In addi-
tion, anti-cancer immune responses may be initiated or boosted
by vaccination with autologous tumor antigen loaded pDCs (60).
A preliminary clinical trial using pDCs in melanoma vaccination
therapy, carried out by our department, has demonstrated the use
of thick born virus vaccine (FSME)-matured pDCS in cancer vac-
cination is safe and feasible, and despite low patients numbers,
showed an improved survival of pDCs vaccinated patients (60).
In particular, the extremely low doses ranging from 0.5 to 3 mil-
lion pDC per patient demonstrate the potency of these cells. The
exact reason for the success of pDCs however is not yet completely
understood, but in addition to IFN-α production and the induc-
tion of tumor-specific T cells, we envision there may also be a
significant role for the effective combination of surface receptors
expressed by the pDCs and their resulting interaction with other
immune cells.
In conclusion, research over the past few years has greatly
increased our knowledge of the repertoire of pDC-expressed sur-
face receptors and cellular interaction partners, and has empha-
sized that there is more to the pDCs than IFN-α alone. Impor-
tantly, however, further studies are required to identify the role of
these molecules and interactions in pDC function and immune
responses in general.
ACKNOWLEDGMENTS
The authors would like to thank Dr. Jurjen Tel (Radboud Uni-
versity Nijmegen), Dr. John-Paul Jukes (University of Oxford),
Rosanna McEwen-Smith (University of Oxford), and Sandhya
Ramalingam Venkateswari Subbammal (London School of Eco-
nomics, London) for the critical reading of our manuscript. This
work was supported by a RUNMC-NCMLS JO grant and grant
KUN2009-4402 from the Dutch Cancer Society. Carl G. Figdor
was awarded with an NWO Spinoza prize and an ERC Advanced
grant (ERC-2010-AdG-269019-PATHFINDER).
REFERENCES
1. Robbins SH, Walzer T, Dembele D, Thibault C, Defays A, Bessou G, et al. Novel
insights into the relationships between dendritic cell subsets in human and
Frontiers in Immunology | Molecular Innate Immunity November 2013 | Volume 4 | Article 372 | 10
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mathan et al. Direct pDC – immune cell interactions
mouse revealed by genome-wide expression profiling. Genome Biol (2008)
9(1):R17. doi:10.1186/gb-2008-9-1-r17
2. Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage:
ontogeny and function of dendritic cells and their subsets in the steady state
and the inflamed setting. Annu Rev Immunol (2013) 31:563–604. doi:10.1146/
annurev-immunol-020711-074950
3. Crozat K, Guiton R, Guilliams M, Henri S, Baranek T, Schwartz-Cornil I, et al.
Comparative genomics as a tool to reveal functional equivalences between
human and mouse dendritic cell subsets. Immunol Rev (2010) 234(1):177–98.
doi:10.1111/j.0105-2896.2009.00868.x
4. Collin M, McGovern N, Haniffa M. Human dendritic cell subsets. Immunology
(2013) 140(1):22–30. doi:10.1111/imm.12117
5. Tel J, Schreibelt G, Sittig SP, Mathan TS, Buschow SI, Cruz LJ, et al. Human
plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T
cells despite lower Ag uptake than myeloid dendritic cell subsets. Blood (2013)
121(3):459–67. doi:10.1182/blood-2012-06-435644
6. Tel J, Hato SV, Torensma R, Buschow SI, Figdor CG, Lesterhuis WJ, et al.
The chemotherapeutic drug oxaliplatin differentially affects blood DC func-
tion dependent on environmental cues. Cancer Immunol Immunother (2012)
61(7):1101–11. doi:10.1007/s00262-011-1189-x
7. Schreibelt G, Tel J, Sliepen KH, Benitez-Ribas D, Figdor CG, Adema GJ,
et al. Toll-like receptor expression and function in human dendritic cell
subsets: implications for dendritic cell-based anti-cancer immunotherapy.
Cancer Immunol Immunother (2010) 59(10):1573–82. doi:10.1007/s00262-
010-0833-1
8. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, et al.
Subsets of human dendritic cell precursors express different toll-like receptors
and respond to different microbial antigens. J Exp Med (2001) 194(6):863–9.
doi:10.1084/jem.194.6.863
9. Cantisani R, Sammicheli C, Tavarini S, D’Oro U, Wack A, Piccioli D. Surface
molecules on stimulated plasmacytoid dendritic cells are sufficient to cross-
activate resting myeloid dendritic cells. Hum Immunol (2011) 72(11):1018–21.
doi:10.1016/j.humimm.2011.08.008
10. McGreal EP, Miller JL, Gordon S. Ligand recognition by antigen-presenting cell
C-type lectin receptors. Curr Opin Immunol (2005) 17(1):18–24. doi:10.1016/
j.coi.2004.12.001
11. Blomberg S, Eloranta ML, Magnusson M, Alm GV, Ronnblom L. Expression
of the markers BDCA-2 and BDCA-4 and production of interferon-alpha by
plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Rheum
(2003) 48(9):2524–32. doi:10.1002/art.11225
12. Schreibelt G, Klinkenberg LJ, Cruz LJ, Tacken PJ, Tel J, Kreutz M, et al.
The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-
)presentation by human blood BDCA3+ myeloid dendritic cells. Blood (2012)
119(10):2284–92. doi:10.1182/blood-2011-08-373944
13. Geijtenbeek TB, van Vliet SJ, Engering A, t Hart BA, van Kooyk Y. Self- and
nonself-recognition by C-type lectins on dendritic cells. Annu Rev Immunol
(2004) 22:33–54. doi:10.1146/annurev.immunol.22.012703.104558
14. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity.
Nat Immunol (2004) 5(12):1219–26. doi:10.1038/ni1141
15. Liu YJ. IPC: professional type 1 interferon-producing cells and plasma-
cytoid dendritic cell precursors. Annu Rev Immunol (2005) 23:275–306.
doi:10.1146/annurev.immunol.23.021704.115633
16. Gilliet M, Cao W, Liu YJ. Plasmacytoid dendritic cells: sensing nucleic
acids in viral infection and autoimmune diseases. Nat Rev Immunol (2008)
8(8):594–606. doi:10.1038/nri2358
17. Manh TP, Alexandre Y, Baranek T, Crozat K, Dalod M. Plasmacytoid, conven-
tional, and monocyte-derived dendritic cells undergo a profound and conver-
gent genetic reprogramming during their maturation. Eur J Immunol (2013)
43(7):1706–15. doi:10.1002/eji.201243106
18. Pulendran B. Variegation of the immune response with dendritic cells and
pathogen recognition receptors. J Immunol (2005) 174(5):2457–65.
19. Martin-Gayo E, Sierra-Filardi E, Corbi AL, Toribio ML. Plasmacytoid dendritic
cells resident in human thymus drive natural Treg cell development. Blood
(2010) 115(26):5366–75. doi:10.1182/blood-2009-10-248260
20. Hanabuchi S, Ito T, Park WR, Watanabe N, Shaw JL, Roman E, et al. Thymic
stromal lymphopoietin-activated plasmacytoid dendritic cells induce the gen-
eration of FOXP3+ regulatory T cells in human thymus. J Immunol (2010)
184(6):2999–3007. doi:10.4049/jimmunol.0804106
21. Fonteneau JF, Gilliet M, Larsson M, Dasilva I, Munz C, Liu YJ, et al. Activa-
tion of influenza virus-specific CD4+ and CD8+ T cells: a new role for plas-
macytoid dendritic cells in adaptive immunity. Blood (2003) 101(9):3520–6.
doi:10.1182/blood-2002-10-3063
22. Reizis B, Bunin A, Ghosh HS, Lewis KL, Sisirak V. Plasmacytoid dendritic cells:
recent progress and open questions. Annu Rev Immunol (2011) 29:163–83.
doi:10.1146/annurev-immunol-031210-101345
23. Swiecki M, Gilfillan S, Vermi W, Wang Y, Colonna M. Plasmacytoid dendritic
cell ablation impacts early interferon responses and antiviral NK and CD8(+)
T cell accrual. Immunity (2010) 33(6):955–66. doi:10.1016/j.immuni.2010.11.
020
24. Donhauser N, Pritschet K, Helm M, Harrer T, Schuster P, Ries M, et al. Chronic
immune activation in HIV-1 infection contributes to reduced interferon alpha
production via enhanced CD40:CD40 ligand interaction. PLoS One (2012)
7(3):e33925. doi:10.1371/journal.pone.0033925
25. Donaghy H, Bosnjak L, Harman AN, Marsden V, Tyring SK, Meng TC,
et al. Role for plasmacytoid dendritic cells in the immune control of recur-
rent human herpes simplex virus infection. J Virol (2009) 83(4):1952–61.
doi:10.1128/JVI.01578-08
26. Lui G, Manches O, Angel J, Molens JP, Chaperot L, Plumas J. Plasmacytoid
dendritic cells capture and cross-present viral antigens from influenza-virus
exposed cells. PLoS One (2009) 4(9):e7111. doi:10.1371/journal.pone.0007111
27. Tel J, Torensma R, Figdor CG, de Vries IJ. IL-4 and IL-13 alter plasmacytoid
dendritic cell responsiveness to CpG DNA and herpes simplex virus-1. J Invest
Dermatol (2011) 131(4):900–6. doi:10.1038/jid.2010.410
28. Pichyangkul S, Endy TP, Kalayanarooj S, Nisalak A, Yongvanitchit K, Green S,
et al. A blunted blood plasmacytoid dendritic cell response to an acute systemic
viral infection is associated with increased disease severity. J Immunol (2003)
171(10):5571–8.
29. Svensson H, Cederblad B, Lindahl M,Alm G. Stimulation of natural interferon-
alpha/beta-producing cells by Staphylococcus aureus. J Interferon Cytokine Res
(1996) 16(1):7–16.
30. Bauer M, Redecke V, Ellwart JW, Scherer B, Kremer JP, Wagner H, et al. Bacter-
ial CpG-DNA triggers activation and maturation of human CD11c-, CD123+
dendritic cells. J Immunol (2001) 166(8):5000–7.
31. Moseman EA, Liang X, Dawson AJ, Panoskaltsis-Mortari A, Krieg AM, Liu
YJ, et al. Human plasmacytoid dendritic cells activated by CpG oligodeoxynu-
cleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol
(2004) 173(7):4433–42.
32. Montoya M, Schiavoni G, Mattei F, Gresser I, Belardelli F, Borrow P, et al. Type
I interferons produced by dendritic cells promote their phenotypic and func-
tional activation. Blood (2002) 99(9):3263–71. doi:10.1182/blood.V99.9.3263
33. Le Bon A, Etchart N, Rossmann C, Ashton M, Hou S, Gewert D, et al. Cross-
priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat
Immunol (2003) 4(10):1009–15. doi:10.1038/ni978
34. Le Bon A, Schiavoni G, D’Agostino G, Gresser I, Belardelli F, Tough DF. Type
i interferons potently enhance humoral immunity and can promote isotype
switching by stimulating dendritic cells in vivo. Immunity (2001) 14(4):461–70.
doi:10.1016/S1074-7613(01)00126-1
35. Krug A, Towarowski A, Britsch S, Rothenfusser S, Hornung V, Bals R, et al.
Toll-like receptor expression reveals CpG DNA as a unique microbial stim-
ulus for plasmacytoid dendritic cells which synergizes with CD40 ligand
to induce high amounts of IL-12. Eur J Immunol (2001) 31(10):3026–37.
doi:10.1002/1521-4141(2001010)31:10<3026::AID-IMMU3026>3.0.CO;2-H
36. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small
anti-viral compounds activate immune cells via the TLR7 MyD88-dependent
signaling pathway. Nat Immunol (2002) 3(2):196–200. doi:10.1038/ni758
37. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW, et al. Recog-
nition of single-stranded RNA viruses by toll-like receptor 7. Proc Natl Acad
Sci U S A (2004) 101(15):5598–603. doi:10.1073/pnas.0400937101
38. Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, Akira S, et al.
Human TLR9 confers responsiveness to bacterial DNA via species-specific
CpG motif recognition. Proc Natl Acad Sci U S A (2001) 98(16):9237–42.
doi:10.1073/pnas.161293498
39. Kerkmann M, Rothenfusser S, Hornung V, Towarowski A, Wagner M, Sarris A,
et al. Activation with CpG-A and CpG-B oligonucleotides reveals two distinct
regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic
cells. J Immunol (2003) 170(9):4465–74.
www.frontiersin.org November 2013 | Volume 4 | Article 372 | 11
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mathan et al. Direct pDC – immune cell interactions
40. Kerkmann M, Costa LT, Richter C, Rothenfusser S, Battiany J, Hornung V, et al.
Spontaneous formation of nucleic acid-based nanoparticles is responsible for
high interferon-alpha induction by CpG-A in plasmacytoid dendritic cells.
J Biol Chem (2005) 280(9):8086–93. doi:10.1074/jbc.M410868200
41. Tel J, Benitez-Ribas D, Hoosemans S, Cambi A, Adema GJ, Figdor CG,
et al. DEC-205 mediates antigen uptake and presentation by both resting
and activated human plasmacytoid dendritic cells. Eur J Immunol (2011)
41(4):1014–23. doi:10.1002/eji.201040790
42. Guery L, Hugues S. Tolerogenic and activatory plasmacytoid dendritic
cells in autoimmunity. Front Immunol (2013) 4:59. doi:10.3389/fimmu.2013.
00059
43. Meyer-Wentrup F, Benitez-Ribas D, Tacken PJ, Punt CJ, Figdor CG, de Vries IJ,
et al. Targeting DCIR on human plasmacytoid dendritic cells results in antigen
presentation and inhibits IFN-alpha production. Blood (2008) 111(8):4245–53.
doi:10.1182/blood-2007-03-081398
44. Tel J, Beenhakker N, Koopman G, Hart B, Mudde GC, de Vries IJ. Targeted
delivery of CpG ODN to CD32 on human and monkey plasmacytoid dendritic
cells augments IFNalpha secretion. Immunobiology (2012) 217(10):1017–24.
doi:10.1016/j.imbio.2012.01.016
45. Benitez-Ribas D, Adema GJ, Winkels G, Klasen IS, Punt CJ, Figdor CG, et al.
Plasmacytoid dendritic cells of melanoma patients present exogenous pro-
teins to CD4+ T cells after Fc gamma RII-mediated uptake. J Exp Med (2006)
203(7):1629–35. doi:10.1084/jem.20052364
46. Conrad C, Meller S, Gilliet M. Plasmacytoid dendritic cells in the skin: to
sense or not to sense nucleic acids. Semin Immunol (2009) 21(3):101–9.
doi:10.1016/j.smim.2009.01.004
47. Sozzani S,Vermi W, Del Prete A, Facchetti F. Trafficking properties of plasmacy-
toid dendritic cells in health and disease. Trends Immunol (2010) 31(7):270–7.
doi:10.1016/j.it.2010.05.004
48. Vermi W, Riboldi E, Wittamer V, Gentili F, Luini W, Marrelli S, et al. Role of
ChemR23 in directing the migration of myeloid and plasmacytoid dendritic
cells to lymphoid organs and inflamed skin. J Exp Med (2005) 201(4):509–15.
doi:10.1084/jem.20041310
49. Benlahrech A, Donaghy H, Rozis G, Goodier M, Klavinskis L, Gotch F,
et al. Human NK cell up-regulation of CD69, HLA-DR, interferon gamma
secretion and cytotoxic activity by plasmacytoid dendritic cells is regulated
through overlapping but different pathways. Sensors (2009) 9(1):386–403.
doi:10.3390/s90100386
50. Hanabuchi S,Watanabe N,WangYH,WangYH,Ito T,Shaw J,et al. Human plas-
macytoid predendritic cells activate NK cells through glucocorticoid-induced
tumor necrosis factor receptor-ligand (GITRL). Blood (2006) 107(9):3617–23.
doi:10.1182/blood-2005-08-3419
51. Rosen DB, Cao W, Avery DT, Tangye SG, Liu YJ, Houchins JP, et al. Func-
tional consequences of interactions between human NKR-P1A and its ligand
LLT1 expressed on activated dendritic cells and B cells. J Immunol (2008)
180(10):6508–17.
52. Banchereau J, Pascual V, Palucka AK. Autoimmunity through cytokine-induced
dendritic cell activation. Immunity (2004) 20(5):539–50. doi:10.1016/S1074-
7613(04)00108-6
53. Kohrgruber N, Groger M, Meraner P, Kriehuber E, Petzelbauer P, Brandt S,
et al. Plasmacytoid dendritic cell recruitment by immobilized CXCR3 ligands.
J Immunol (2004) 173(11):6592–602.
54. Bangert C, Friedl J, Stary G, Stingl G, Kopp T. Immunopathologic fea-
tures of allergic contact dermatitis in humans: participation of plasmacytoid
dendritic cells in the pathogenesis of the disease? J Invest Dermatol (2003)
121(6):1409–18. doi:10.1111/j.1523-1747.2003.12623.x
55. Penna G, Sozzani S, Adorini L. Cutting edge: selective usage of chemokine
receptors by plasmacytoid dendritic cells. J Immunol (2001) 167(4):1862–6.
56. Seth S, Oberdorfer L, Hyde R, Hoff K, Thies V, Worbs T, et al. CCR7 essen-
tially contributes to the homing of plasmacytoid dendritic cells to lymph
nodes under steady-state as well as inflammatory conditions. J Immunol (2011)
186(6):3364–72. doi:10.4049/jimmunol.1002598
57. de la Rosa G, Longo N, Rodriguez-Fernandez JL, Puig-Kroger A, Pineda A,
Corbi AL, et al. Migration of human blood dendritic cells across endothelial cell
monolayers: adhesion molecules and chemokines involved in subset-specific
transmigration. J Leukoc Biol (2003) 73(5):639–49. doi:10.1189/jlb.1002516
58. Krug A, Uppaluri R, Facchetti F, Dorner BG, Sheehan KC, Schreiber RD, et al.
IFN-producing cells respond to CXCR3 ligands in the presence of CXCL12
and secrete inflammatory chemokines upon activation. J Immunol (2002)
169(11):6079–83.
59. Vanbervliet B, Bendriss-Vermare N, Massacrier C, Homey B, de Bouteiller O,
Briere F, et al. The inducible CXCR3 ligands control plasmacytoid dendritic
cell responsiveness to the constitutive chemokine stromal cell-derived fac-
tor 1 (SDF-1)/CXCL12. J Exp Med (2003) 198(5):823–30. doi:10.1084/jem.
20020437
60. Tel J, Aarntzen EH, Baba T, Schreibelt G, Schulte BM, Benitez-Ribas D,
et al. Natural human plasmacytoid dendritic cells induce antigen-specific
T-cell responses in melanoma patients. Cancer Res (2013) 73(3):1063–75.
doi:10.1158/0008-5472.CAN-12-2583
61. Sisirak V, Vey N, Vanbervliet B, Duhen T, Puisieux I, Homey B, et al.
CCR6/CCR10-mediated plasmacytoid dendritic cell recruitment to inflamed
epithelia after instruction in lymphoid tissues. Blood (2011) 118(19):5130–40.
doi:10.1182/blood-2010-07-295626
62. Banchereau J, Pulendran B, Steinman R, Palucka K. Will the making of plasma-
cytoid dendritic cells in vitro help unravel their mysteries? J Exp Med (2000)
192(12):F39–44. doi:10.1084/jem.192.12.F39
63. Facchetti F, Vermi W, Mason D, Colonna M. The plasmacytoid mono-
cyte/interferon producing cells. Virchows Arch (2003) 443(6):703–17. doi:10.
1007/s00428-003-0918-8
64. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasma-
cytoid dendritic cells induce plasma cell differentiation through type I inter-
feron and interleukin 6. Immunity (2003) 19(2):225–34. doi:10.1016/S1074-
7613(03)00208-5
65. Garcia-Marquez M, Shimabukuro-Vornhagen A, von Bergwelt-Baildon M.
Complex interactions between B cells and dendritic cells. Blood (2013)
121(12):2367–8. doi:10.1182/blood-2012-12-468017
66. Marschner A, Rothenfusser S, Hornung V, Prell D, Krug A, Kerkmann M, et al.
CpG ODN enhance antigen-specific NKT cell activation via plasmacytoid den-
dritic cells. Eur J Immunol (2005) 35(8):2347–57. doi:10.1002/eji.200425721
67. Conrad C, Gregorio J, Wang YH, Ito T, Meller S, Hanabuchi S, et al. Plas-
macytoid dendritic cells promote immunosuppression in ovarian cancer
via ICOS costimulation of Foxp3(+) T-regulatory cells. Cancer Res (2012)
72(20):5240–9. doi:10.1158/0008-5472.CAN-12-2271
68. Faget J, Bendriss-Vermare N, Gobert M, Durand I, Olive D, Biota C, et al.
ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer
progression by promoting the accumulation of immunosuppressive CD4+
T cells. Cancer Res (2012) 72(23):6130–41. doi:10.1158/0008-5472.CAN-12-
2409
69. Mai J, Virtue A, Shen J, Wang H, Yang XF. An evolving new paradigm: endothe-
lial cells – conditional innate immune cells. J Hematol Oncol (2013) 6:61.
doi:10.1186/1756-8722-6-61
70. Zabel BA, Silverio AM, Butcher EC. Chemokine-like receptor 1 expression and
chemerin-directed chemotaxis distinguish plasmacytoid from myeloid den-
dritic cells in human blood. J Immunol (2005) 174(1):244–51.
71. Albanesi C, Scarponi C, Pallotta S, Daniele R, Bosisio D, Madonna S, et al.
Chemerin expression marks early psoriatic skin lesions and correlates with
plasmacytoid dendritic cell recruitment. J Exp Med (2009) 206(1):249–58.
doi:10.1084/jem.20080129
72. Schuster P, Boscheinen JB, Tennert K, Schmidt B. The role of plasmacytoid
dendritic cells in innate and adaptive immune responses against alpha herpes
virus infections. Adv Virol (2011) 2011:679271. doi:10.1155/2011/679271
73. Fuhlbrigge RC, King SL, Sackstein R, Kupper TS. CD43 is a ligand for E-
selectin on CLA+ human T cells. Blood (2006) 107(4):1421–6. doi:10.1182/
blood-2005-05-2112
74. Schuster P, Donhauser N, Pritschet K, Ries M, Haupt S, Kittan NA, et al.
Co-ordinated regulation of plasmacytoid dendritic cell surface receptors
upon stimulation with herpes simplex virus type 1. Immunology (2010)
129(2):234–47. doi:10.1111/j.1365-2567.2009.03176.x
75. Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, Lanzavecchia A,
et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce
large amounts of type I interferon. Nat Med (1999) 5(8):919–23. doi:10.1038/
11360
76. Guillerme JB, Boisgerault N, Roulois D, Menager J, Combredet C, Tangy
F, et al. Measles virus vaccine-infected tumor cells induce tumor antigen
cross-presentation by human plasmacytoid dendritic cells. Clin Cancer Res
(2013) 19(5):1147–58. doi:10.1158/1078-0432.CCR-12-2733
Frontiers in Immunology | Molecular Innate Immunity November 2013 | Volume 4 | Article 372 | 12
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mathan et al. Direct pDC – immune cell interactions
77. Tel J, Lambeck AJ, Cruz LJ, Tacken PJ, de Vries IJ, Figdor CG. Human plasma-
cytoid dendritic cells phagocytose, process, and present exogenous particulate
antigen. J Immunol (2010) 184(8):4276–83. doi:10.4049/jimmunol.0903286
78. Di Pucchio T, Chatterjee B, Smed-Sorensen A, Clayton S, Palazzo A, Montes
M, et al. Direct proteasome-independent cross-presentation of viral antigen by
plasmacytoid dendritic cells on major histocompatibility complex class I. Nat
Immunol (2008) 9(5):551–7. doi:10.1038/ni.1602
79. Nierkens S, Tel J, Janssen E, Adema GJ. Antigen cross-presentation by dendritic
cell subsets: one general or all sergeants? Trends Immunol (2013) 34(8):361–70.
doi:10.1016/j.it.2013.02.007
80. Kuwana M, Kaburaki J, Wright TM, Kawakami Y, Ikeda Y. Induction of antigen-
specific human CD4(+) T cell anergy by peripheral blood DC2 precursors. Eur
J Immunol (2001) 31(9):2547–57. doi:10.1002/1521-4141(200109)31:9<2547:
:AID-IMMU2547>3.0.CO;2-J
81. Grouard G, Rissoan MC, Filgueira L, Durand I, Banchereau J, Liu YJ. The enig-
matic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3
and CD40-ligand. J Exp Med (1997) 185(6):1101–11. doi:10.1084/jem.185.6.
1101
82. Kadowaki N, Antonenko S, Lau JY, Liu YJ. Natural interferon alpha/beta-
producing cells link innate and adaptive immunity. J Exp Med (2000)
192(2):219–26. doi:10.1084/jem.192.2.219
83. Ito T, Yang M, Wang YH, Lande R, Gregorio J, Perng OA, et al. Plasmacy-
toid dendritic cells prime IL-10-producing T regulatory cells by inducible
costimulator ligand. J Exp Med (2007) 204(1):105–15. doi:10.1084/jem.
20061660
84. Ogata M, Ito T, Shimamoto K, Nakanishi T, Satsutani N, Miyamoto R, et al.
Plasmacytoid dendritic cells have a cytokine-producing capacity to enhance
ICOS ligand-mediated IL-10 production during T-cell priming. Int Immunol
(2013) 25(3):171–82. doi:10.1093/intimm/dxs103
85. Ito T, Amakawa R, Inaba M, Ikehara S, Inaba K, Fukuhara S. Differential reg-
ulation of human blood dendritic cell subsets by IFNs. J Immunol (2001)
166(5):2961–9.
86. Rissoan MC, Soumelis V, Kadowaki N, Grouard G, Briere F, de Waal Malefyt
R, et al. Reciprocal control of T helper cell and dendritic cell differentiation.
Science (1999) 283(5405):1183–6. doi:10.1126/science.283.5405.1183
87. Cella M, Facchetti F, Lanzavecchia A, Colonna M. Plasmacytoid dendritic cells
activated by influenza virus and CD40L drive a potent TH1 polarization. Nat
Immunol (2000) 1(4):305–10. doi:10.1038/79747
88. Karrich JJ, Jachimowski LC, Nagasawa M, Kamp A, Balzarolo M, Wolkers MC,
et al. IL-21-stimulated human plasmacytoid dendritic cells secrete granzyme
B, which impairs their capacity to induce T-cell proliferation. Blood (2013)
121(16):3103–11. doi:10.1182/blood-2012-08-452995
89. Flies DB, Chen L. The new B7s: playing a pivotal role in tumor immunity.
J Immunother (2007) 30(3):251–60. doi:10.1097/CJI.0b013e31802e085a
90. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance
and immunity. Annu Rev Immunol (2008) 26:677–704. doi:10.1146/annurev.
immunol.26.021607.090331
91. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement
of PD-L1 on tumor cells in the escape from host immune system and
tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A (2002)
99(19):12293–7. doi:10.1073/pnas.192461099
92. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, et al. Blockade
of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic
immunity. Cancer Res (2005) 65(3):1089–96.
93. Ito T, Amakawa R, Inaba M, Hori T, Ota M, Nakamura K, et al. Plasmacytoid
dendritic cells regulate Th cell responses through OX40 ligand and type I IFNs.
J Immunol (2004) 172(7):4253–9.
94. Delespesse G, Ohshima Y, Yang LP, Demeure C, Sarfati M. OX40-Mediated
cosignal enhances the maturation of naive human CD4+ T cells into high
IL-4-producing effectors. Int Arch Allergy Immunol (1999) 118(2–4):384–6.
doi:10.1159/000024143
95. Beignon AS, McKenna K, Skoberne M, Manches O, DaSilva I, Kavanagh DG,
et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via toll-
like receptor-viral RNA interactions. J Clin Invest (2005) 115(11):3265–75.
doi:10.1172/JCI26032
96. Chaperot L, Blum A, Manches O, Lui G, Angel J, Molens JP, et al. Virus or TLR
agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic
cells. J Immunol (2006) 176(1):248–55.
97. Stary G, Klein I, Kohlhofer S, Koszik F, Scherzer T, Mullauer L, et al. Plasmacy-
toid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1
viremic patients. Blood (2009) 114(18):3854–63. doi:10.1182/blood-2009-04-
217927
98. Dillon SM, Robertson KB, Pan SC, Mawhinney S, Meditz AL, Folkvord JM,
et al. Plasmacytoid and myeloid dendritic cells with a partial activation phe-
notype accumulate in lymphoid tissue during asymptomatic chronic HIV-1
infection. J Acquir Immune Defic Syndr (2008) 48(1):1–12. doi:10.1097/QAI.
0b013e3181664b60
99. Germain C, Meier A, Jensen T, Knapnougel P, Poupon G, Lazzari A, et al.
Induction of lectin-like transcript 1 (LLT1) protein cell surface expression by
pathogens and interferon-gamma contributes to modulate immune responses.
J Biol Chem (2011) 286(44):37964–75. doi:10.1074/jbc.M111.285312
100. Montaldo E, Vitale C, Cottalasso F, Conte R, Glatzer T, Ambrosini P, et al.
Human NK cells at early stages of differentiation produce CXCL8 and
express CD161 molecule that functions as an activating receptor. Blood (2012)
119(17):3987–96. doi:10.1182/blood-2011-09-379693
101. Rosen DB, Bettadapura J, Alsharifi M, Mathew PA, Warren HS, Lanier LL. Cut-
ting edge: lectin-like transcript-1 is a ligand for the inhibitory human NKR-P1A
receptor. J Immunol (2005) 175(12):7796–9.
102. Bossard C, Malard F, Arbez J, Chevallier P, Guillaume T, Delaunay J, et al.
Plasmacytoid dendritic cells and Th17 immune response contribution in gas-
trointestinal acute graft-versus-host disease. Leukemia (2012) 26(7):1471–4.
doi:10.1038/leu.2012.41
103. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ,Van Kaer L. NKT cells:
what’s in a name? Nat Rev Immunol (2004) 4(3):231–7. doi:10.1038/nri1309
104. Montoya CJ, Jie HB, Al-Harthi L, Mulder C, Patino PJ, Rugeles MT, et al. Acti-
vation of plasmacytoid dendritic cells with TLR9 agonists initiates invariant
NKT cell-mediated cross-talk with myeloid dendritic cells. J Immunol (2006)
177(2):1028–39.
105. Kadowaki N, Antonenko S, Ho S, Rissoan MC, Soumelis V, Porcelli SA,
et al. Distinct cytokine profiles of neonatal natural killer T cells after expan-
sion with subsets of dendritic cells. J Exp Med (2001) 193(10):1221–6.
doi:10.1084/jem.193.10.1221
106. Jukes JP, Wood KJ, Jones ND. Bystander activation of iNKT cells occurs dur-
ing conventional T-cell alloresponses. Am J Transplant (2012) 12(3):590–9.
doi:10.1111/j.1600-6143.2011.03847.x
107. Brigl M, Tatituri RV, Watts GF, Bhowruth V, Leadbetter EA, Barton N, et al.
Innate and cytokine-driven signals, rather than microbial antigens, dominate
in natural killer T cell activation during microbial infection. J Exp Med (2011)
208(6):1163–77. doi:10.1084/jem.20102555
108. Diana J, Griseri T, Lagaye S, Beaudoin L, Autrusseau E, Gautron AS, et al. NKT
cell-plasmacytoid dendritic cell cooperation via OX40 controls viral infec-
tion in a tissue-specific manner. Immunity (2009) 30(2):289–99. doi:10.1016/
j.immuni.2008.12.017
109. Zaini J, Andarini S, Tahara M, Saijo Y, Ishii N, Kawakami K, et al. OX40 ligand
expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity
in mice. J Clin Invest (2007) 117(11):3330–8. doi:10.1172/JCI32693
110. Shimizu K, Asakura M, Shinga J, Sato Y, Kitahara S, Hoshino K, et al. Invariant
NKT cells induce plasmacytoid dendritic cell (DC) cross-talk with conven-
tional DCs for efficient memory CD8+ T cell induction. J Immunol (2013)
190(11):5609–19. doi:10.4049/jimmunol.1300033
111. Bekeredjian-Ding IB, Wagner M, Hornung V, Giese T, Schnurr M, Endres S,
et al. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via
type I IFN. J Immunol (2005) 174(7):4043–50.
112. Braun D, Caramalho I, Demengeot J. IFN-alpha/beta enhances BCR-dependent
B cell responses. Int Immunol (2002) 14(4):411–9. doi:10.1093/intimm/14.4.
411
113. Shaw J, Wang YH, Ito T, Arima K, Liu YJ. Plasmacytoid dendritic cells regu-
late B-cell growth and differentiation via CD70. Blood (2010) 115(15):3051–7.
doi:10.1182/blood-2009-08-239145
114. Berggren O, Hagberg N, Weber G, Alm GV, Ronnblom L, Eloranta ML. B lym-
phocytes enhance interferon-alpha production by plasmacytoid dendritic cells.
Arthritis Rheum (2012) 64(10):3409–19. doi:10.1002/art.34599
115. Vermi W, Lonardi S, Morassi M, Rossini C, Tardanico R, Venturini M, et al.
Cutaneous distribution of plasmacytoid dendritic cells in lupus erythemato-
sus. Selective tropism at the site of epithelial apoptotic damage. Immunobiology
(2009) 214(9–10):877–86. doi:10.1016/j.imbio.2009.06.013
www.frontiersin.org November 2013 | Volume 4 | Article 372 | 13
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mathan et al. Direct pDC – immune cell interactions
116. Nascimbeni M, Perie L, Chorro L, Diocou S, Kreitmann L, Louis S, et al. Plas-
macytoid dendritic cells accumulate in spleens from chronically HIV-infected
patients but barely participate in interferon-alpha expression. Blood (2009)
113(24):6112–9. doi:10.1182/blood-2008-07-170803
117. Perez-Cabezas B, Naranjo-Gomez M, Ruiz-Riol M, Bastos-Amador P, Fernan-
dez MA, Carmona F, et al. TLR-activated conventional DCs promote gamma-
secretase-mediated conditioning of plasmacytoid DCs. J Leukoc Biol (2012)
92(1):133–43. doi:10.1189/jlb.0911452
118. Piccioli D, Sammicheli C, Tavarini S, Nuti S, Frigimelica E, Manetti AG, et al.
Human plasmacytoid dendritic cells are unresponsive to bacterial stimula-
tion and require a novel type of cooperation with myeloid dendritic cells
for maturation. Blood (2009) 113(18):4232–9. doi:10.1182/blood-2008-10-
186890
119. Flacher V, Bouschbacher M, Verronese E, Massacrier C, Sisirak V, Berthier-
Vergnes O, et al. Human Langerhans cells express a specific TLR profile and
differentially respond to viruses and Gram-positive bacteria. J Immunol (2006)
177(11):7959–67.
120. Means TK, Hayashi F, Smith KD, Aderem A, Luster AD. The toll-like receptor 5
stimulus bacterial flagellin induces maturation and chemokine production in
human dendritic cells. J Immunol (2003) 170(10):5165–75.
121. Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A.
Specialization and complementarity in microbial molecule recognition
by human myeloid and plasmacytoid dendritic cells. Eur J Immunol
(2001) 31(11):3388–93. doi:10.1002/1521-4141(200111)31:11<3388::AID-
IMMU3388>3.0.CO;2-Q
122. Ito T, Amakawa R, Kaisho T, Hemmi H, Tajima K, Uehira K, et al. Interferon-
alpha and interleukin-12 are induced differentially by toll-like receptor 7 lig-
ands in human blood dendritic cell subsets. J Exp Med (2002) 195(11):1507–12.
doi:10.1084/jem.20020207
123. Ito T, Wang YH, Liu YJ. Plasmacytoid dendritic cell precursors/type I
interferon-producing cells sense viral infection by toll-like receptor (TLR) 7
and TLR9. Springer Semin Immunopathol (2005) 26(3):221–9. doi:10.1007/
s00281-004-0180-4
124. Barchet W, Cella M, Colonna M. Plasmacytoid dendritic cells – virus experts of
innate immunity. Semin Immunol (2005) 17(4):253–61. doi:10.1016/j.smim.
2005.05.008
125. Bond E, Liang F, Sandgren KJ, Smed-Sorensen A, Bergman P, Brighenti S,
et al. Plasmacytoid dendritic cells infiltrate the skin in positive tuberculin skin
test indurations. J Invest Dermatol (2012) 132(1):114–23. doi:10.1038/jid.2011.
246
126. Fonteneau JF, Larsson M, Beignon AS, McKenna K, Dasilva I, Amara A, et al.
Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells
and concomitantly induces the bystander maturation of myeloid dendritic
cells. J Virol (2004) 78(10):5223–32. doi:10.1128/JVI.78.10.5223-5232.2004
127. Lebedeva T, Dustin ML, Sykulev Y. ICAM-1 co-stimulates target cells to facil-
itate antigen presentation. Curr Opin Immunol (2005) 17(3):251–8. doi:10.
1016/j.coi.2005.04.008
128. Mocikat R, Braumuller H, Gumy A, Egeter O, Ziegler H, Reusch U, et al. Nat-
ural killer cells activated by MHC class I(low) targets prime dendritic cells
to induce protective CD8 T cell responses. Immunity (2003) 19(4):561–9.
doi:10.1016/S1074-7613(03)00264-4
129. Mailliard RB, Son YI, Redlinger R, Coates PT, Giermasz A, Morel PA, et al.
Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal
requirement for the induction of NK cell helper function. J Immunol (2003)
171(5):2366–73.
130. Romagnani C, Della Chiesa M, Kohler S, Moewes B, Radbruch A, Moretta L,
et al. Activation of human NK cells by plasmacytoid dendritic cells and its
modulation by CD4+ T helper cells and CD4+ CD25hi T regulatory cells. Eur
J Immunol (2005) 35(8):2452–8. doi:10.1002/eji.200526069
131. Wehner R, Dietze K, Bachmann M, Schmitz M. The bidirectional crosstalk
between human dendritic cells and natural killer cells. J Innate Immun (2011)
3(3):258–63. doi:10.1159/000323923
132. Gerosa F, Gobbi A, Zorzi P, Burg S, Briere F, Carra G, et al. The reciprocal inter-
action of NK cells with plasmacytoid or myeloid dendritic cells profoundly
affects innate resistance functions. J Immunol (2005) 174(2):727–34.
133. Trinchieri G, Santoli D, Koprowski H. Spontaneous cell-mediated cytotoxic-
ity in humans: role of interferon and immunoglobulins. J Immunol (1978)
120(6):1849–55.
134. Hagberg N, Berggren O, Leonard D, Weber G, Bryceson YT, Alm GV, et al.
IFN-alpha production by plasmacytoid dendritic cells stimulated with RNA-
containing immune complexes is promoted by NK cells via MIP-1beta and
LFA-1. J Immunol (2011) 186(9):5085–94. doi:10.4049/jimmunol.1003349
135. Evans JH, Horowitz A, Mehrabi M, Wise EL, Pease JE, Riley EM, et al. A dis-
tinct subset of human NK cells expressing HLA-DR expand in response to IL-2
and can aid immune responses to BCG. Eur J Immunol (2011) 41(7):1924–33.
doi:10.1002/eji.201041180
136. Marshall JD, Heeke DS, Abbate C, Yee P, Van Nest G. Induction of interferon-
gamma from natural killer cells by immunostimulatory CpG DNA is mediated
through plasmacytoid-dendritic-cell-produced interferon-alpha and tumour
necrosis factor-alpha. Immunology (2006) 117(1):38–46. doi:10.1111/j.1365-
2567.2005.02261.x
137. Fauriat C, Long EO, Ljunggren HG, Bryceson YT. Regulation of human NK-cell
cytokine and chemokine production by target cell recognition. Blood (2010)
115(11):2167–76. doi:10.1182/blood-2009-08-238469
138. Della Chiesa M, Romagnani C, Thiel A, Moretta L, Moretta A. Multidi-
rectional interactions are bridging human NK cells with plasmacytoid and
monocyte-derived dendritic cells during innate immune responses. Blood
(2006) 108(12):3851–8. doi:10.1182/blood-2006-02-004028
139. Aldemir H, Prod’homme V, Dumaurier MJ, Retiere C, Poupon G, Cazareth J,
et al. Cutting edge: lectin-like transcript 1 is a ligand for the CD161 receptor. J
Immunol (2005) 175(12):7791–5.
140. Beckebaum S, Zhang X, Chen X, Yu Z, Frilling A, Dworacki G, et al. Increased
levels of interleukin-10 in serum from patients with hepatocellular carci-
noma correlate with profound numerical deficiencies and immature pheno-
type of circulating dendritic cell subsets. Clin Cancer Res (2004) 10(21):7260–9.
doi:10.1158/1078-0432.CCR-04-0872
141. Pinzon-Charry A, Ho CS, Maxwell T, McGuckin MA, Schmidt C, Furnival C,
et al. Numerical and functional defects of blood dendritic cells in early- and
late-stage breast cancer. Br J Cancer (2007) 97(9):1251–9. doi:10.1038/sj.bjc.
6604018
142. van Cruijsen H, Hoekman K, Stam AG, van den Eertwegh AJ, Kuenen BC,
Scheper RJ, et al. Defective differentiation of myeloid and plasmacytoid den-
dritic cells in advanced cancer patients is not normalized by tyrosine kinase
inhibition of the vascular endothelial growth factor receptor. Clin Dev Immunol
(2007) 2007:17315. doi:10.1155/2007/17315
143. Karthaus N, Torensma R, Tel J. Deciphering the message broadcast by tumor-
infiltrating dendritic cells. Am J Pathol (2012) 181(3):733–42. doi:10.1016/j.
ajpath.2012.05.012
144. Charles J, Di Domizio J, Salameire D, Bendriss-Vermare N, Aspord C, Muham-
mad R, et al. Characterization of circulating dendritic cells in melanoma: role
of CCR6 in plasmacytoid dendritic cell recruitment to the tumor. J Invest Der-
matol (2010) 130(6):1646–56. doi:10.1038/jid.2010.24
145. Hasan L, Mazzucchelli L, Liebi M, Lis M, Hunger RE, Tester A, et al. Func-
tion of liver activation-regulated chemokine/CC chemokine ligand 20 is dif-
ferently affected by cathepsin B and cathepsin D processing. J Immunol (2006)
176(11):6512–22.
146. Movassagh M, Spatz A, Davoust J, Lebecque S, Romero P, Pittet M, et al.
Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites
is associated with efficient T-cell-mediated antitumor response and control
of metastatic dissemination in melanoma. Cancer Res (2004) 64(6):2192–8.
doi:10.1158/0008-5472.CAN-03-2969
147. Lee JR, Dalton RR, Messina JL, Sharma MD, Smith DM, Burgess RE, et al.
Pattern of recruitment of immunoregulatory antigen-presenting cells in
malignant melanoma. Lab Invest (2003) 83(10):1457–66. doi:10.1097/01.LAB.
0000090158.68852.D1
148. Demoulin S, Herfs M, Delvenne P, Hubert P. Tumor microenvironment con-
verts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells:
insight into the molecular mechanisms. J Leukoc Biol (2013) 93(3):343–52.
doi:10.1189/jlb.0812397
149. Bekeredjian-Ding I, Schafer M, Hartmann E, Pries R, Parcina M, Schneider
P, et al. Tumour-derived prostaglandin E and transforming growth factor-
beta synergize to inhibit plasmacytoid dendritic cell-derived interferon-alpha.
Immunology (2009) 128(3):439–50. doi:10.1111/j.1365-2567.2009.03134.x
150. Thiel A, Pries R, Jeske S, Trenkle T, Wollenberg B. Effect of head and neck cancer
supernatant and CpG-oligonucleotides on migration and IFN-alpha produc-
tion of plasmacytoid dendritic cells. Anticancer Res (2009) 29(8):3019–25.
Frontiers in Immunology | Molecular Innate Immunity November 2013 | Volume 4 | Article 372 | 14
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mathan et al. Direct pDC – immune cell interactions
151. Ara T, Song L, Shimada H, Keshelava N, Russell HV, Metelitsa LS, et al.
Interleukin-6 in the bone marrow microenvironment promotes the growth
and survival of neuroblastoma cells. Cancer Res (2009) 69(1):329–37. doi:10.
1158/0008-5472.CAN-08-0613
152. Kamohara H, Takahashi M, Ishiko T, Ogawa M, Baba H. Induction
of interleukin-8 (CXCL-8) by tumor necrosis factor-alpha and leukemia
inhibitory factor in pancreatic carcinoma cells: impact of CXCL-8 as an
autocrine growth factor. Int J Oncol (2007) 31(3):627–32.
153. Brew R, Erikson JS, West DC, Kinsella AR, Slavin J, Christmas SE. Interleukin-
8 as an autocrine growth factor for human colon carcinoma cells in vitro.
Cytokine (2000) 12(1):78–85. doi:10.1006/cyto.1999.0518
154. Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, Sandman Y, et al.
Interleukin-8 is a molecular determinant of androgen independence and pro-
gression in prostate cancer. Cancer Res (2007) 67(14):6854–62. doi:10.1158/
0008-5472.CAN-07-1162
155. Yao C, Lin Y, Chua MS, Ye CS, Bi J, Li W, et al. Interleukin-8 modulates growth
and invasiveness of estrogen receptor-negative breast cancer cells. Int J Cancer
(2007) 121(9):1949–57. doi:10.1002/ijc.22930
156. Fan Y, Ye J, Shen F, Zhu Y, Yeghiazarians Y, Zhu W, et al. Interleukin-6
stimulates circulating blood-derived endothelial progenitor cell angiogenesis
in vitro. J Cereb Blood Flow Metab (2008) 28(1):90–8. doi:10.1038/sj.jcbfm.
9600509
157. Li A, Dubey S, Varney ML, Dave BJ, Singh RK. IL-8 directly enhanced endothe-
lial cell survival, proliferation, and matrix metalloproteinases production and
regulated angiogenesis. J Immunol (2003) 170(6):3369–76.
158. Brat DJ, Bellail AC, Van Meir EG. The role of interleukin-8 and its receptors
in gliomagenesis and tumoral angiogenesis. Neuro Oncol (2005) 7(2):122–33.
doi:10.1215/S1152851704001061
159. Cao W, Bover L. Signaling and ligand interaction of ILT7: receptor-mediated
regulatory mechanisms for plasmacytoid dendritic cells. Immunol Rev (2010)
234(1):163–76. doi:10.1111/j.0105-2896.2009.00867.x
160. Walter-Yohrling J, Cao X, Callahan M, Weber W, Morgenbesser S, Madden SL,
et al. Identification of genes expressed in malignant cells that promote invasion.
Cancer Res (2003) 63(24):8939–47.
161. Ohtomo T, Sugamata Y, Ozaki Y, Ono K, Yoshimura Y, Kawai S, et al. Mol-
ecular cloning and characterization of a surface antigen preferentially over-
expressed on multiple myeloma cells. Biochem Biophys Res Commun (1999)
258(3):583–91. doi:10.1006/bbrc.1999.0683
162. Erikson E, Adam T, Schmidt S, Lehmann-Koch J, Over B, Goffinet C, et al.
In vivo expression profile of the antiviral restriction factor and tumor-targeting
antigen CD317/BST-2/HM1.24/tetherin in humans. Proc Natl Acad Sci U S A
(2011) 108(33):13688–93. doi:10.1073/pnas.1101684108
163. Cao W. Molecular characterization of human plasmacytoid dendritic cells.
J Clin Immunol (2009) 29(3):257–64. doi:10.1007/s10875-009-9284-x
164. Cao W, Rosen DB, Ito T, Bover L, Bao M, Watanabe G, et al. Plasmacytoid
dendritic cell-specific receptor ILT7-Fc epsilonRI gamma inhibits toll-like
receptor-induced interferon production. J Exp Med (2006) 203(6):1399–405.
doi:10.1084/jem.20052454
165. Cho M, Ishida K, Chen J, Ohkawa J, Chen W, Namiki S, et al. SAGE library
screening reveals ILT7 as a specific plasmacytoid dendritic cell marker that reg-
ulates type I IFN production. Int Immunol (2008) 20(1):155–64. doi:10.1093/
intimm/dxm127
166. Ju XS, Hacker C, Scherer B, Redecke V, Berger T, Schuler G, et al.
Immunoglobulin-like transcripts ILT2, ILT3 and ILT7 are expressed by
human dendritic cells and down-regulated following activation. Gene (2004)
331:159–64. doi:10.1016/j.gene.2004.02.018
167. Chang CC, Ciubotariu R, Manavalan JS,Yuan J, Colovai AI, Piazza F, et al. Toler-
ization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors
ILT3 and ILT4. Nat Immunol (2002) 3(3):237–43. doi:10.1038/ni760
168. Shiroishi M, Tsumoto K, Amano K, Shirakihara Y, Colonna M, Braud VM, et al.
Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with
CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad
Sci U S A (2003) 100(15):8856–61. doi:10.1073/pnas.1431057100
169. Fuchs A, Cella M, Kondo T, Colonna M. Paradoxic inhibition of human nat-
ural interferon-producing cells by the activating receptor NKp44. Blood (2005)
106(6):2076–82. doi:10.1182/blood-2004-12-4802
170. Horton NC, Mathew SO, Mathew PA. Novel interaction between proliferating
cell nuclear antigen and HLA I on the surface of tumor cells inhibits NK cell
function through NKp44. PLoS One (2013) 8(3):e59552. doi:10.1371/journal.
pone.0059552
171. Kalb ML, Glaser A, Stary G, Koszik F, Stingl G. TRAIL(+) human plasmacy-
toid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and
IFN-alpha-mediated antitumor reactivity. J Immunol (2012) 188(4):1583–91.
doi:10.4049/jimmunol.1102437
172. Tel J, Smits EL, Anguille S, Joshi RN, Figdor CG, de Vries IJ. Human plas-
macytoid dendritic cells are equipped with antigen-presenting and tumori-
cidal capacities. Blood (2012) 120(19):3936–44. doi:10.1182/blood-2012-06-
435941
173. Vigneswaran N, Baucum DC, Wu J, Lou Y, Bouquot J, Muller S, et al. Repres-
sion of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but
not its receptors during oral cancer progression. BMC Cancer (2007) 7:108.
doi:10.1186/1471-2407-7-108
174. Calpe S, Wang N, Romero X, Berger SB, Lanyi A, Engel P, et al. The SLAM
and SAP gene families control innate and adaptive immune responses. Adv
Immunol (2008) 97:177–250. doi:10.1016/S0065-2776(08)00004-7
175. Cabezon R, Sintes J, Llinas L, Benitez-Ribas D. Analysis of HLDA9 mAbs on
plasmacytoid dendritic cells. Immunol Lett (2011) 134(2):167–73. doi:10.1016/
j.imlet.2010.09.020
176. Cannons JL, Qi H, Lu KT, Dutta M, Gomez-Rodriguez J, Cheng J, et al. Optimal
germinal center responses require a multistage T cell:B cell adhesion process
involving integrins, SLAM-associated protein, and CD84. Immunity (2010)
32(2):253–65. doi:10.1016/j.immuni.2010.01.010
177. Gopcsa L, Banyai A, Jakab K, Kormos L, Tamaska J, Matolcsy A, et al. Extensive
flow cytometric characterization of plasmacytoid dendritic cell leukemia cells.
Eur J Haematol (2005) 75(4):346–51. doi:10.1111/j.1600-0609.2005.00513.x
178. Oliver-Vila I, Saborit-Villarroya I, Engel P, Martin M. The leukocyte receptor
CD84 inhibits Fc epsilon RI-mediated signaling through homophilic inter-
action in transfected RBL-2H3 cells. Mol Immunol (2008) 45(8):2138–49.
doi:10.1016/j.molimm.2007.12.006
179. Romero X, Zapater N, Calvo M, Kalko SG, de la Fuente MA, Tovar V,
et al. CD229 (Ly9) lymphocyte cell surface receptor interacts homophilically
through its N-terminal domain and relocalizes to the immunological synapse.
J Immunol (2005) 174(11):7033–42.
180. Bouchon A, Cella M, Grierson HL, Cohen JI, Colonna M. Activation of NK
cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family. J
Immunol (2001) 167(10):5517–21.
181. Boles KS, Mathew PA. Molecular cloning of CS1, a novel human natural killer
cell receptor belonging to the CD2 subset of the immunoglobulin superfamily.
Immunogenetics (2001) 52(3–4):302–7. doi:10.1007/s002510000274
182. Lee JK, Mathew SO, Vaidya SV, Kumaresan PR, Mathew PA. CS1 (CRACC,
CD319) induces proliferation and autocrine cytokine expression on human B
lymphocytes. J Immunol (2007) 179(7):4672–8.
183. Stark S, Watzl C. 2B4 (CD244), NTB-A and CRACC (CS1) stimulate cytotoxi-
city but no proliferation in human NK cells. Int Immunol (2006) 18(2):241–7.
doi:10.1093/intimm/dxh358
184. Falco M, Marcenaro E, Romeo E, Bellora F, Marras D, Vely F, et al. Homophilic
interaction of NTBA, a member of the CD2 molecular family: induction of
cytotoxicity and cytokine release in human NK cells. Eur J Immunol (2004)
34(6):1663–72. doi:10.1002/eji.200424886
185. Flaig RM, Stark S, Watzl C. Cutting edge: NTB-A activates NK cells via
homophilic interaction. J Immunol (2004) 172(11):6524–7.
186. Messmer B, Eissmann P, Stark S, Watzl C. CD48 stimulation by 2B4 (CD244)-
expressing targets activates human NK cells. J Immunol (2006) 176(8):4646–50.
187. Tel J, van der Leun AM, Figdor CG, Torensma R, de Vries IJ. Harnessing
human plasmacytoid dendritic cells as professional APCs. Cancer Immunol
Immunother (2012) 61(8):1279–88. doi:10.1007/s00262-012-1210-z
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 17 September 2013; paper pending published: 02 October 2013; accepted: 29
October 2013; published online: 12 November 2013.
Citation: Mathan TSM, Figdor CG and Buschow SI (2013) Human plasmacytoid den-
dritic cells: from molecules to intercellular communication network. Front. Immunol.
4:372. doi: 10.3389/fimmu.2013.00372
www.frontiersin.org November 2013 | Volume 4 | Article 372 | 15
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mathan et al. Direct pDC – immune cell interactions
This article was submitted to Molecular Innate Immunity, a section of the journal
Frontiers in Immunology.
Copyright © 2013 Mathan, Figdor and Buschow. This is an open-access article dis-
tributed under the terms of the Creative Commons Attribution License (CC BY). The
use, distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal is cited,
in accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
Frontiers in Immunology | Molecular Innate Immunity November 2013 | Volume 4 | Article 372 | 16
